References
- Aldousari S, Kassouf W. Update on the management of non-muscle invasive bladder cancer. Can Urol Assoc J. 2010;4(1):56–64.
- MacKenzie T, Zens MS, Ferrara A, Schned A, Karagas MR. Diabetes and risk of bladder cancer: evidence from a case-control study in New England. Cancer. 2011;117(7):1552–1556.
- Hwang EC, Kim YJ, Hwang IS, Hwang JE, Jung SI, Kwon DD, Park K, Ryu SB. Impact of diabetes mellitus on recurrence and progression in patients with non-muscle invasive bladder carcinoma: a retrospective cohort study. Int J Urol. 2011;18(11):769–776.
- Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.
- Kamat AM, Flaig TW, Grossman HB, Konety B, Lamm D, O'Donnell MA, Uchio E, Efstathiou JA, Taylor JA. Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol.. 2015;12(4):225.
- American Diabetes A. Standards of medical care in diabetes–2011. Diabetes Care. 2011;34:S11–S61.
- Snorgaard O, Pg Andersen HK, Astrup A. Systematic review and meta-analysis of dietary carbohydrate restriction in patients with type 2 diabetes. BMJ Open Diabetes Res Care. 2017;5:e000354.
- Gross LS, Li L, Ford ES, Liu S. Increased consumption of refined carbohydrates and the epidemic of type 2 diabetes in the United States: an ecologic assessment. Am J Clin Nutr. 2004;79(5):774–779.
- Kim C-H, Kim H-K, Kim E-H, Bae S-J, Choe J, Park J-Y. Longitudinal changes in insulin resistance, beta-cell function and glucose regulation status in prediabetes. Am J Med Sci. 2018;355(1):54–60.
- Carlson AL, Mullen DM, Bergenstal RM. Clinical use of continuous glucose monitoring in adults with type 2 diabetes. Diabetes Technol Ther. 2017;19(S2):S4–S11.
- Ross R. Does exercise without weight loss improve insulin sensitivity? Diabetes Care. 2003;26(3):944–945.
- Nipp RD, Powell E, Chabner B, Moy B. Recognizing the financial burden of cancer patients in clinical trials. Oncologist. 2015;20(6):572–575.